Trends of the primary therapy for patients with prostate cancer in nara uro-oncological research group (NUORG): A comparison between the CaPSURE data and the NUORG data

Japanese Journal of Clinical Oncology

Volumn 40, Issue 6, 2010, Pages 588-592

  Tanaka, Nobumichi ^a   Fujimoto, Kiyohide ^a   Hirayama, Akihide ^a   Yoneda, Tatsuo ^a   Yoshida, Katsunori ^a   Hirao, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Gleason score; Primary therapy; Prostate cancer; Risk classification; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; GLEASON SCORE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; PROSTATE CANCER; PROSTATECTOMY; UNITED STATES; WATCHFUL WAITING; BLOOD; COMPARATIVE STUDY; JAPAN; MALE; PATHOLOGY; PROSTATE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; JAPAN; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; UNITED STATES;

EID: 77953423280     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq008     Document Type: Article

References (11)

1. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170:S21-S27.
2. Sirovich BE, Schwartz LM, Woloshin S. Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? J Am Med Assoc 2003;289:1414-20.
3. Ito K, Kakehi Y, Naito S, Okuyama A,. Japanese Urological Association. Japanese Urological Association guidelines on prostate-specific antigen-based screening for prostate cancer and the ongoing cluster cohort study in Japan. Int J Urol 2008;15:763-8.
4. Cooperberg MR, Lubeck DP, Penson DF, Mehta SS, Carroll PR, Kane CJ. Sociodemographic and clinical risk characteristics of patients with prostate cancer within the Veterans Affairs health care system: data from CaPSURE. J Urol 2003;170:905-8.
5. Cancer. Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005;12:46-61.
6. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 1998;280:969-74.
7. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007;178:S14-S19.
8. Akaza H, Usami M, Hinotsu S, Ogawa O, Kagawa S, Kitamura T, et al. Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol 2004;34:329-36.
9. Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Sci 2006;97:243-7.
10. Akaza H, Hinotsu S, Usami M, Ogawa O, Kagawa S, Kitamura T, et al. The case for androgen deprivation as primary therapy for early stage disease: results from J-CaP and CaPSURE. J Urol 2006;176:S47-S49.
11. Tanaka N, Asakawa I, Kondo H, Tanaka M, Fujimoto K, Hasegawa M, et al. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients. Int J Urol 2009;16:70-4.